Structural basis for broad coronavirus neutralization

Sauer, Maximilian M.; Tortorici, M. Alexandra; Park, Young-Jun; Walls, Alexandra C.; Homad, Leah; Acton, Oliver; Bowen, John; Wang, Chunyan; Xiong, Xiaoli; de van der Schueren, Willem; Quispe, Joel; Hoffstrom, Benjamin G.; Bosch, Berend-Jan; McGuire, Andrew T.; Veesler, David

Three highly pathogenic β-coronaviruses crossed the animal-to-human species barrier in the past two decades: SARS-CoV, MERS-CoV and SARS-CoV-2. SARS-CoV-2 has infected more than 64 million people worldwide, claimed over 1.4 million lives and is responsible for the ongoing COVID-19 pandemic. We isolated a monoclonal antibody, termed B6, cross-reacting with eight β-coronavirus spike glycoproteins, including all five human-infecting β-coronaviruses, and broadly inhibiting entry of pseudotyped viruses from two coronavirus lineages. Cryo-electron microscopy and X-ray crystallography characterization reveal that B6 binds to a conserved cryptic epitope located in the fusion machinery and indicate that antibody binding sterically interferes with spike conformational changes leading to membrane fusion. Our data provide a structural framework explaining B6 cross-reactivity with β-coronaviruses from three lineages along with proof-of-concept for antibody-mediated broad coronavirus neutralization elicited through vaccination. This study unveils an unexpected target for next-generation structure-guided design of a pan-coronavirus vaccine.